Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

Journal of Virology

Volumn 76, Issue 4, 2002, Pages 1753-1761

  Brenner, Bluma G ^a   Routy, Jean Pierre ^a   Petrella, Marco ^a   Moisi, Daniela ^a   Oliveira, Maureen ^a   Detorio, Mervi ^a   Spira, Bonnie ^a   Essabag, Vidal ^a   Conway, Brian ^a   Lalonde, Richard ^a   Sekaly, Rafick Pierre ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PERSISTENT VIRUS INFECTION; PHENOTYPE; PRIMARY INFECTION; PRIORITY JOURNAL; VIREMIA; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0036149707     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.4.1753-1761.2002     Document Type: Article

References (34)

1. Persistence of HIV-1 variants harbouring the zidovudine mutation at pol codon 215 in patients who respond to triple combination therapy
2. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
3. HIV-1 drug resistance in newly infected individuals
4. Changes in natural immunity during the course of HIV-1 infection
5. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up
6. HIV population dynamics in vivo: Implications for genetic variability, pathogenesis and therapy
7. Selective vertical transmission of HIV-1 antiretroviral resistance mutations
8. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
9. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
10. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum
11. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
12. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection
13. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
14. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
15. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management
16. Quantitative assays for virus infectivity
17. Reduced drug susceptibility among patients with primary HIV infection
18. Estimating relative fitness in viral competition experiments
19. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
20. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
21. Selective vertical transmission of HIV: Lamuvidine-resistant maternal clone undetectable by conventional resistance testing
22. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
23. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
24. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1
25. Prevalence of HIV-1 viruses resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or intravenous drug use
26. Comparison of DNA sequencing and a line probe assay for detection of a human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy
27. Attenuated replication of a human immunodeficiency virus type 1 didanosine-selected reverse transcriptase mutation
28. Long term persistence of zidovudine resistance mutations of plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine treated patients removed from zidovudine therapy
29. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
30. Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy
31. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
32. Public health implications of antiretroviral therapy and HIV drug resistance
33. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase
34. Transmission of antiretroviral-drug-resistant HIV-1 variants